Novo Nordisk enters collaboration with Heartseed on cell-based treatment

Through the new agreement, Novo Nordisk gets exclusive rights to develop, produce and market Heartseed's HS-001 product for the treatment of cardiovascular diseases all over the world, excluding Japan.

Photo: Stine Tidsvilde

Novo Nordisk and Heartseed have entered an exclusive global partnership and license agreement over the development, production and marketing of Heartseed's HS-001 to treat cardiovascular diseases, Novo Nordisk reports in a press release.

HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs